Edgar Filing: Luly Jay R. - Form 4

Form 4							
FORM 4 UNITED					-	PPROVAL	
UNITED		RITIES AND EXC ashington, D.C. 205		COMMISSION	OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or				Estimated average burden hours per			
	(a) of the Public U	16(a) of the Securiti Jtility Holding Com nvestment Company	npany Act	of 1935 or Sectio	·		
(Print or Type Responses)							
1. Name and Address of Reporting Luly Jay R.	Symbol	2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS		5. Relationship of Reporting Person(s) to Issuer			
	INC [F		(Check all applicable)				
(Last) (First) (C/O ENANTA PHARMACEUTICALS, IN ARSENAL STREET	(Month/ 11/16/	of Earliest Transaction Day/Year) 2018		X Director X Officer (give below) Pres		% Owner ler (specify	
(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
WATERTOWN, MA 02472	, ,				More than One R		
(City) (State)	(Zip) Tal	ole I - Non-Derivative S	Securities A	cquired, Disposed o	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		(A) or of (D)	SecuritiesHBeneficially(Owned(5. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate line	e for each class of sec	curities beneficially own	ed directly o	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Luly Jay R. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 81.2	11/16/2018		A	68,000	<u>(1)</u>	11/16/2028	Common Stock	68,000	
Reporting Owners										

Reporting Owner Name / Address	Relationships			
Reporting Owner Mane / Mar ess	Director	10% Owner	Officer	
Luly Jay R. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN, MA 02472	Х		President and CEO	
Signatures				
/s/ Nathaniel S. Gardiner as attorney-in-fact	11/20/2	2018		

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (1) (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole

share equivalent is accumulated) over four years from the date of grant (November 16, 2018).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Other